Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.04
Infliximab (TNF-a antibody) data in IBD model
We introduce some of the data, the results for Infliximab (TNF-a antibody), from the full version of the IBD model materials. Infliximab (TNF-a antibody) shows the improvement in the fibrosis area compared to the DSS group. For more detailed data, please contact us using the form below.
2025.02.04
Latest IBD Models Materials
We are pleased to introduce the latest materials showcasing our DSS induced IBD model, designed to provide valuable insights for your pre-clinical research. You can download the digest version here: (This version includes an overview of the model and an approval drug data) The Full version includes the following content. ・Chronic DSS model…
2025.02.04
Preclinical COPD research with positive controls
We would like to introduce a positive control (Roflumilast) in a drug efficacy evaluation study using PPE-induced COPD model. Our clients previously asked, “Do you have a positive control for COPD trials?” and we have now acquired the data and launched the product. The drug used as a positive control is roflumilast, a PDE-4…
2025.02.03
TAA model: Acute liver failure model
We would like to introduce an acute liver failure (ALF), thioacetamide (TAA)-induced ALF model. For this model, major endpoints in pharmacology studies include histological assessment of hepatic injury and blood biochemistry (ALT and AST). The TAA model is as widely used as ALF model and characterized by hepatocellular necrosis caused by an active metabolite…
2025.02.03
The comparison of NASH-HCC and other HCC models
Today, we present the third part of the comparison table on liver cancer models. Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma (HCC) is known to account for about 90% of all liver cancers. Hepatitis B…
2025.02.03
The STAM model as a model of liver fibrosis
Today, we present the comparison table on fibrosis models of the liver. Liver fibrosis is defined as excessive extracellular matrix deposition preceded by chronic liver injury, which can progress to liver failure. The factors that can cause liver fibrosis include oxidative stress, cholestasis, and NASH. Therefore, when assessing the efficacy of anti-fibrotic compounds, it…
2025.02.03
Silica-induced pulmonary fibrosis model
We would like to introduce you to a Silica-induced pulmonary fibrosis model. This model is suitable for you if you want to evaluate lung fibrosis over a long period of time (e.g. cell therapy) The Silica-induced pulmonary fibrosis model reproduces the pathology of the Silicosis, with the production of reactive oxygen species, cell death…
2025.02.03
In Vitro Assay Service for Fibrosis Evaluation
We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation. By launching this service, we now offer a cost-effective and efficient way to conduct preliminary studies and screen compounds for potential fibrotic effects, saving valuable time and resources in your drug development journey. This not only…
2025.02.03
STAM mouse | Adiponectin-derived peptide study to inhibit MASH and fibrosis progression
Today, we would like to introduce an example of a proof-of-concept study of adiponectin-derived peptide ALY688 in STAMTM mice, which was published in Clinical and Translational Science by a research team from Allysta Pharmaceuticals, Inc. in the United States. The adiponectin – derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepatitis –…
2025.02.03
Lung functional marker in IPF model
We would like to introduce a non-invasive biomarkers for Idiopathic Pulmonary Fibrosis (IPF) disease models. In lung diseases such as idiopathic pulmonary fibrosis, lung function is evaluated along with CT and histopathological analysis of the lung. In the case of mice, evaluation of lung function is not easy to perform due to the complexity…
We can help you advance your research.